US Orthopedic Biomaterial Market to Grow Strongly to $3.7 Billion by 2017

  US Orthopedic Biomaterial Market to Grow Strongly to $3.7 Billion by 2017

Resurgence in Growth in Bone Graft Substitutes, According to Millennium
Research Group

PR Newswire

TORONTO, Jan. 30, 2013

TORONTO, Jan. 30, 2013 /PRNewswire/ --According to Millennium Research Group
(MRG), the global authority on medical technology market intelligence,
demographic trends, a resurgence in the bone graft substitute (BGS) segment
will help the US orthopedic biomaterial market to grow strongly to nearly $3.7
billion by 2017.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36799LOGO)

The BGS segment is still suffering from the effects of the sales decline of
Medtronic's INFUSE product. Although it remains the highest-revenue product in
this segment, INFUSE continues to face challenges associated with waning
off-label use, which has historically made up a significant portion of the
product's sales.

There will, however, be a resurgence in the growth factor market, which will
be driven in part by increasing uptake of Advanced Biologics' OsteoAMP growth
factor product, along with Wright Medical Technology's Augment and Cerapedics'
i-Factor products. The latter two are expected to be approved and launched
before 2017. Cost containment measures at hospitals will curb this resurgence,
however, and many surgeons will opt to use lesser-expensive alternatives,
including orthopedic stem cell products and second-generation synthetics.

"Although orthopedic stem cell products are facing some challenges in coverage
due to a lack of robust clinical data, they will continue to see strong
increases in use," said MRG Analyst Mashkur Reza. "With the launch of new
products, such as Biomet's Cellentra, the demand for orthopedic stem cell
products will continue to grow fairly strongly. Other competitors are more
than likely to follow suit and will compete against the likes of Biomet and
NuVasive, the latter of which leads the segment with its Osteocel product."

Through 2017, the fastest-growing segment in the US orthopedic biomaterials
market will be hyaluronic acid (HA) viscosupplementation, as patients
increasingly opt for more convenient, and also more expensive,
single-injection HA treatments. The cell concentration systems segment will
also contribute to growth in the market.

Millennium Research Group's US Markets for Orthopedic Biomaterials 2013 report
includes unit, average selling price and revenue information, along with
market drivers and limiters and competitive landscape for BGS, hyaluronic acid
viscosupplementation, machined bone interbody devices, and cell concentration
systems in the United States.

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company
(www.DecisionResourcesGroup.com), is the global authority on medical
technology market intelligence and the leading provider of strategic
information to the healthcare sector. The company provides specialized
industry expertise through multiclient market research, ongoing Marketrack™
projects, customer loyalty tracking, facility-level procedure forecasting, and
customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information, and insights on important sectors of
the healthcare industry. Clients rely on this analysis and data to make
informed decisions. Please visit Decision Resources Group at
www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort      Alex Jablokow
Decision Resources Group Millennium Research Group
781-993-2597             617-599-8613
ccomfort@dresources.com  ajablokow@mrg.net



SOURCE Millennium Research Group

Website: http://www.MRG.net